{"filing":{"accession_number":"0001493152-26-034077","cik":"0001679628","ticker":"JUNS","company_name":"JUPITER NEUROSCIENCES, INC.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/form8-k.htm"},"events":[{"id":19099,"run_id":17187,"accession_number":"0001493152-26-034077","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Jupiter Neurosciences entered into a definitive Strategic Asset License Agreement with PharmAla Biotech on July 20, 2026, granting an exclusive royalty-bearing license to develop, manufacture, and commercialize ALA-002 products in the United States. The transaction involves $3.3M upfront consideration (cash and equity), up to $23.3M in development milestones, up to $73.3M in commercialization milestones, and 3% royalties on net sales. This constitutes a material acquisition of intellectual property rights and represents a significant strategic transaction for a clinical-stage pharmaceutical company.","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":18095,"accession_number":"0001493152-26-034077","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Jupiter Neurosciences entered into a definitive Strategic Asset License Agreement with PharmAla Biotech on July 20, 2026, granting an exclusive royalty-bearing license to develop, manufacture, and commercialize ALA-002 products in the United States. The transaction involves $3.3M upfront consideration (cash and equity), up to $23.3M in development milestones, up to $73.3M in commercialization milestones, and 3% royalties on net sales. This constitutes a material acquisition of intellectual property rights and represents a significant strategic transaction for a clinical-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:07:09.446516+00:00","company_name":"JUPITER NEUROSCIENCES, INC.","ticker":"JUNS","filing_date":"2026-07-21"}]}